Post by Uncle on Oct 2, 2015 18:37:40 GMT
In retrospect for those who missed. Here is a May 2014 WKMJ (World Korean Medical Journal) interview on Dr. Phillip Frost. Now if you remember, Opko's Licensee Tesaro on July 30, 2015 inked a license agreement with China's Jiangsu Hengrui Medicine Co., Ltd for Rolapitant.
Tesaro FORM 10-Q For the quarterly period ended June 30, 2015 states that the royalty rate on annual net sales of Rolapitant outside of the United States and Europe is slightly above the single digits.
Tesaro will pay royalties on Rolapitant until the later of the date that all of the patent rights licensed from OPKO and covering Rolapitant expire, are invalidated or are not enforceable, and 12 years from the first commercial sale of the product, in each case, on a country-by-country and product-by-product basis.
If Tesaro elects to develop and commercialize Rolapitant in Japan through a third-party licensee, Tesaro will share equally with OPKO all amounts received by us in connection with such activities under our agreement with such third party, subject to certain exceptions and deductions.
OPKO retains an option to become the exclusive distributor of such products in Latin America, provided that OPKO exercises that option within a defined period following specified regulatory approvals in the United States.
About the World Strategy Group who also publishes the WKMJ (World Korean Medical Journal)
'Focused on the entire healthcare value chain, and armed with special knowledge of and contacts in East Asia, W Medical Strategy Group provides far-sighted analysis, in-depth research and rapid real-time advice to enable the life sciences industry to enhance the quality of life by expanding access to new, innovative medicines, medical devices and diagnostics. With its multidisciplinary team of physicians and expert consultants, W Medical Strategy Group also integrates specialized industry expertise, ethnic perspective, and vision to guide healthcare providers facing crucial business decisions.'
World Korean Medical Journal May 2014
Our aim is to fill every issue with a variety of information from technology, pharmaceuticals, and health care policy. In our Entrepreneur Interview, we meet Dr. Phillip Frost of OPKO Health Inc. A physician, a CEO, and a leader in healthcare arena, Dr. Frost advises young physicians to be entrepreneurial and to embrace change as new business models are being developed to treat the aging population.
Tesaro FORM 10-Q For the quarterly period ended June 30, 2015 states that the royalty rate on annual net sales of Rolapitant outside of the United States and Europe is slightly above the single digits.
Tesaro will pay royalties on Rolapitant until the later of the date that all of the patent rights licensed from OPKO and covering Rolapitant expire, are invalidated or are not enforceable, and 12 years from the first commercial sale of the product, in each case, on a country-by-country and product-by-product basis.
If Tesaro elects to develop and commercialize Rolapitant in Japan through a third-party licensee, Tesaro will share equally with OPKO all amounts received by us in connection with such activities under our agreement with such third party, subject to certain exceptions and deductions.
OPKO retains an option to become the exclusive distributor of such products in Latin America, provided that OPKO exercises that option within a defined period following specified regulatory approvals in the United States.
About the World Strategy Group who also publishes the WKMJ (World Korean Medical Journal)
'Focused on the entire healthcare value chain, and armed with special knowledge of and contacts in East Asia, W Medical Strategy Group provides far-sighted analysis, in-depth research and rapid real-time advice to enable the life sciences industry to enhance the quality of life by expanding access to new, innovative medicines, medical devices and diagnostics. With its multidisciplinary team of physicians and expert consultants, W Medical Strategy Group also integrates specialized industry expertise, ethnic perspective, and vision to guide healthcare providers facing crucial business decisions.'
World Korean Medical Journal May 2014
Our aim is to fill every issue with a variety of information from technology, pharmaceuticals, and health care policy. In our Entrepreneur Interview, we meet Dr. Phillip Frost of OPKO Health Inc. A physician, a CEO, and a leader in healthcare arena, Dr. Frost advises young physicians to be entrepreneurial and to embrace change as new business models are being developed to treat the aging population.